LOS ANGELES — Celgene will pay $280 million to the United States, 28 states and the District of Columbia to settle claims it promoted cancer drugs Thalomid and Revlimid for unapproved uses and submitted fraudulent Medicare and Medi-Cal claims for it, federal prosecutors said Tuesday.
Categories / Health
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
EU says member states can use bloc’s funds for ‘safe’ abortion access February 26, 2026 -
-
Veterans urge Second Circuit to lower bar for IVF benefits February 26, 2026 -
Truancy or special needs? February 25, 2026